Summary

Drug-eluting stents confer no additional late cardiovascular risk in patients with stenting of large coronary arteries when compared with bare-metal stents according to the results of the 24-month Basel Stent Cost-effectiveness Trial-PROspective Evaluation Examination [BASKET-PROVE; ISRCTN72444640].